Last updated: September 10, 2024
Sponsor: University of Alberta
Overall Status: Completed
Phase
2
Condition
Urothelial Carcinoma
Bladder Cancer
Urothelial Cancer
Treatment
High-Intensity Interval Training
Clinical Study ID
NCT04593862
HEBRA - CC 20-0184
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Eligible participants will include men and women that (1) are ≥ 18 years old, (2)have a confirmed diagnosis of non-muscle invasive bladder cancer (clinical stagecis, Ta or T1), and (3) are scheduled to receive induction intravesical therapy withchemotherapy (e.g., Gemcitabine or Mitomycin) or immunotherapy (e.g., BCG) agents.
Exclusion
Exclusion Criteria:
- Exclusion criteria for participants include: (1) not being medically cleared toparticipate in the exercise intervention by their treating urologist and a certifiedexercise physiologist using the Physical Activity Readiness Questionnaire forEveryone (PAR-Q+), (2) having contraindications for cardiopulmonary stress and/orphysical fitness tests, (3) already exercising according to the Godin Leisure-TimeExercise Questionnaire (GLTEQ), (4) not having the ability to read and comprehendEnglish, and (5) not willing to be randomized to a supervised exercise trainingprogram or usual care (no exercise) for 12 weeks.
Study Design
Total Participants: 25
Treatment Group(s): 1
Primary Treatment: High-Intensity Interval Training
Phase: 2
Study Start date:
December 09, 2021
Estimated Completion Date:
August 30, 2024
Connect with a study center
Fernanda Zane Arthuso
Edmonton, Alberta
CanadaSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.